Ionis Pharmaceuticals announced positive topline data from its pivotal Phase 3 CORE and CORE2 trials of olearsen in patients with severe hypertriglyceridemia (sHTG). The antisense oligonucleotide demonstrated up to 72% placebo-adjusted triglyceride reduction and an 85% decrease in acute pancreatitis episodes over a year. Safety and tolerability profiles were favorable, with injection site reactions being the most common side effect. The data position olearsen for potential label expansion into a larger hypertriglyceridemia patient population, addressing a significant unmet clinical need.